Moderna (NASDAQ:MRNA) Price Target Raised to $163.00 at Oppenheimer

Moderna (NASDAQ:MRNA) had its price objective boosted by Oppenheimer from $142.00 to $163.00 in a report published on Friday, Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other analysts have also weighed in on the stock. HSBC reissued a reduce rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Needham & Company LLC reissued a hold rating on shares of Moderna in a report on Thursday, May 2nd. Royal Bank of Canada reissued an outperform rating and issued a $125.00 price target on shares of Moderna in a report on Thursday, March 28th. Jefferies Financial Group reissued a buy rating and issued a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Finally, William Blair reissued a market perform rating on shares of Moderna in a report on Monday, April 1st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Moderna has an average rating of Hold and a consensus price target of $129.55.

Moderna Stock Down 2.3 %

NASDAQ MRNA opened at $122.13 on Friday. The firm has a market cap of $46.81 billion, a PE ratio of -7.79 and a beta of 1.57. Moderna has a one year low of $62.55 and a one year high of $142.79. The stock’s 50 day simple moving average is $105.61 and its 200 day simple moving average is $94.76. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna’s revenue for the quarter was down 91.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.19 EPS. As a group, sell-side analysts forecast that Moderna will post -7.47 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now directly owns 8,557 shares of the company’s stock, valued at $809,235.49. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00. Following the sale, the director now directly owns 2,131,931 shares of the company’s stock, valued at approximately $231,399,790.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Shannon Thyme Klinger sold 670 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $63,361.90. Following the completion of the sale, the insider now directly owns 8,557 shares in the company, valued at $809,235.49. The disclosure for this sale can be found here. Insiders have sold a total of 139,954 shares of company stock valued at $14,822,576 over the last three months. 15.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ogorek Anthony Joseph NY ADV acquired a new position in shares of Moderna during the 4th quarter worth about $27,000. Arlington Trust Co LLC grew its stake in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares during the last quarter. Westside Investment Management Inc. acquired a new position in Moderna in the 1st quarter valued at about $32,000. Rise Advisors LLC grew its stake in Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares during the last quarter. Finally, UMB Bank n.a. grew its stake in Moderna by 121.8% in the 1st quarter. UMB Bank n.a. now owns 366 shares of the company’s stock valued at $39,000 after buying an additional 201 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.